| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8929 | Garenoxacin | Garenoxacin is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections. |
|
| DC8893 | Garenoxacin Mesylate hydrate | Garenoxacin mesylate hydrate is a novel oral des-fluoro(6) quinolone with potent antimicrobial activity, against common respiratory pathogens, including resistant strains. |
|
| DC10474 | GBT-440(Voxelotor) Featured | GBT-440(Voxelotor) is a novel small molecule hemoglobin modifier which increases hemoglobin oxygen affinity. |
|
| DC10153 | GDC-0077 Featured | GDC-0077 is an orally available PI3K inhibitor with potential antineoplastic activity. GDC-0077 is extracted from patent WO 2017001645 A1, formula I. |
|
| DC9708 | Paxalisib (GDC-0084) Featured | GDC-0084 （RG7666）, is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. |
|
| DC10485 | GDC0575（ARRY-575，RG7441） Featured | GDC0575（ARRY-575，RG7441）is a small molecule inhibitor of cell cycle checkpoint kinase 1 (Chk1), with potential chemosensitization activity. |
|
| DC9942 | GDC-0853(RG7845) Featured | GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. |
|
| DC3102 | GDC-0879 | GDC-0879 is a novel potent, selective B-Raf inhibitor for B-RafV600E with IC50 of 0.13 nM. |
|
| DC9592 | GDC-0941 (dimethanesulfonate) | GDC-0941 2 MeSO3H salt is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold). |
|
| DC1054 | GDC0941(Pictilisib) Featured | GDC-0941 is a potent inhibitor of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ with IC50 of 3 nM, 33 nM, 3 nM and 75 nM, respectively. |
|
| DC4177 | Cobimetinib(GDC-0973; XL518) Featured | GDC-0973 is a potent, highly selective inhibitor of mitogen-activated protein kinase kinase, also known as MEK, a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. |
|
| DC5081 | Apitolisib Featured | GDC-0980 (RG7422) is a potent, class I PI3K inhibitor for PI3Kα/β/δ/γ with IC50 of 5 nM/27 nM/7 nM/14 nM, respectively. Also a mTOR inhibitor with Ki of 17 nM, and highly selective versus others PIKK family kinases. |
|
| DC10721 | Gefapixant(AF-219,MK-7264) Featured | Gefapixant(AF-219,MK-7264) is novel P2X3 receptor antagonist. |
|
| DC2103 | Gefitinib (ZD1839) Featured | Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
|
| DC2107 | Gemcitabine HCl (Gemzar,LY188011) Featured | Gemcitabine Hydrochloride (Gemzar) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively,showed potent activity against COVID-19(SARS-COV-2) with EC50 MERS-COV(1.216), SARS-COV(4.9 |
|
| DC2108 | Gemcitabine free base | Gemcitabine(Gemzar) belongs to the group of medicines called antimetabolites. |
|
| DC12342 | Gemilukast (ONO-6950) | Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2) antagonist, with IC50s of 1.7, 25 nM for human CysLT1 and CysLT2, respectively. |
|
| DC10161 | Gepotidacin Featured | Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor. |
|
| DC10490 | GIBH-130 Featured | GIBH-130 is a novel inhibitor of neuroinflammation effective in Alzheimer’s disease models. |
|
| DC8946 | Gimeracil | Gimeracil(Gimestat) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood; inhibits homologous recombination. |
|
| DC8118 | GKT137831(Setanaxib) Featured | GKT137831 is a novel and specific dual Nox1/Nox4 inhibitor with Ki of 140±40 nM and 110±30 nM; a potent inhibitor of fibrosis and hepatocyte apoptosis. |
|
| DC10818 | ABT-493(Glecaprevir) Featured | Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. |
|
| DC11803 | GLPG-1690(Ziritaxestat) Featured | GLPG-1690 is a first-in-class, potent, competitive autotaxin inhibitor with Ki/IC50 of 15 nM/131 nM. |
|
| DC10753 | GLPG-1837(ABBV-974) Featured | GLPG-1837(ABBV-974) is a novel cystic fibrosis transmembrane conductance regulator CFTR potentiator. |
|
| DC11678 | GLPG-2222 | GLPG-2222 (ABBV-2222, Galicaftor) is a novel potent and efficacious CFTR corrector with EC50 of 5 nM. |
|
| DC10003 | PF-06291874（glucagon receptor antagonists-4） Featured | glucagon receptor antagonists-4 is a highly potent glucagon receptor antagonist. |
|
| DC11543 | Glumetinib Featured | Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM. |
|
| DC8779 | Glycopyrrolate Featured | Glycopyrrolate(Glycopyrronium Br) is a muscarinic competitive antagonist used as an antispasmodic. |
|
| DC7419 | GNE-7915 Featured | GNE-7915 is a highly potent, selective, and brain-penetrable LRRK2 small molecule inhibitor with IC50 of 9 nM in cellular LRRK2 assay; > 100 fold selectivity against a panel of 187 kianses(Ki). |
|
| DC7137 | Filgotinib(GLPG0634) Featured | Filgotinib (GLPG0634) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib can be used in the study of rheumatoid arthritis and inflammatory bowel disease. |
|
